Dermatophytic onychomycosis (DO) is
characterized as being a fungal infection of the nail. Infection can involve
the nail unit (nail matrix, nail bed, or nail plate). DO isn’t considered
life-threatening, however can cause patients to experience discomfort, pain,
and may cause physical and occupational limitations. DO patients can be
identified as having thick or brittle nails along with discoloration (white and
opaque). Physicians currently use direct microscopy and fungal culture tests to
ensure correct diagnosis and treatment are achieved.
Risk factors such as advanced age,
pre-existing diabetes, or immunocompromised systems can increase the incidence
of DO in patients. Current therapies consist of generics that offer substantial
efficacy but sub-par safety profiles. A new wave of therapies is expected to
offer topical options for patients who are unable to withstand existing generic
options. These therapies are also expected to drive an increase in total drug
treatment rates in the US market.
To
Read The Complete Report with TOC : http://www.marketresearchreports.biz/analysis-details/pharmapoint-dermatophytic-onychomycosis-do-us-drug-forecast-and-market-analysis-to-2022
Scope
- Overview of DO, including
epidemiology, etiology, general symptoms from infection, and disease
management recommendations and guidelines.
- Annualized DO market revenue,
annual cost of therapy and treatment usage pattern data from 2012 and
forecast for ten years to 2022.
- Key topics covered include
strategic competitor assessment, market characterization, unmet needs,
clinical trial mapping and implications for the DO market.
- Pipeline analysis:
comprehensive data split across different phases, and emerging trends,
specifically new therapies with novel routes of administration.
- Analysis of the current and
future market competition in the US DO market. Insightful review of the
key industry and governmental drivers, restraints and challenges. Each
trend is independently researched to provide qualitative analysis of its
implications.
Market Model Features
An interactive excel forecast model
based on primary research interviews and surveys with KOLs and high-prescribing
physicians is included in this report*. This patient based model provides
diagnosis rates, patient segmentation, treatment rates, annual costs of therapy
, and indication-specific drug sales for the 10 year forecast period. The
forecast model is robust, fully transparent, and easy to navigate. Moreover,
our models support data presented in the reports and the complete methodology
is outlined in the report and the model.
*Model only available with site and
global license purchases.
Key Findings
- Generic therapies are expected
to pose as a considerable threat to upcoming topical therapies because of
their shorter treatment duration.
- The first wave of new pipeline
candidates will increase drug treatment rates as physicians begin to opt
for more safer options for treatment.
- Individual compliance, patient
co-morbidities, and insurance payers function as important considerations
in assessing the treatment algorithm for every patient.
Key Questions Answered in this
Report
- How big of an impact will
topical agents have on the DO market? What do key opinion leaders think of
this paradigm shift?
- What new product is expected to
become the market leader during the forecast period? How will this impact
the existing generic therapies?
- How will a change in the route
of administration change the uptake of drugs in the US market?
- What are the primary unmet
needs that exist in the market according to key opinion leaders?
- What alliance opportunities
exist in this market for a company looking to tap into the DO market?
Key Benefits
- Develop and design your
in-licensing and out-licensing strategies through a review of pipeline
products and technologies, and by identifying the companies with the most
robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the US DO market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market segments, and
companies likely to impact the US DO market in future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and by
analyzing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the US DO
market from 2012-2022.
- Organize your sales and marketing
efforts by identifying the market categories and segments that present
maximum opportunities for consolidations, investments and strategic
partnerships.
About
Us
MarketResearchReports.Biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are especially designed to save time and
money of our clients. We are a one stop solution for all your research needs, our
main offerings are syndicated research reports, custom research, subscription
access and consulting services. We serve all sizes and types of companies
spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment